Presentation is loading. Please wait.

Presentation is loading. Please wait.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Published byFanny Pranoto Modified over 6 years ago

Similar presentations

Presentation on theme: "Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,"— Presentation transcript:

1 Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault, MSc, Robert Bissonnette, MD, FRCPC  Journal of the American Academy of Dermatology  Volume 70, Issue 6, Pages (June 2014) DOI: /j.jaad Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Patient disposition.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Notalgia paresthetica. Progression of pruritus (A) and area of hyperpigmentation (B) over time for patients randomized to botulinum toxin A (BTX-A; black diamonds) and placebo (gray squares). Patients initially randomized to placebo received BTX-A at week 12. Number of subjects with hyperpigmentation at baseline were 6 and 7 for placebo and BTX-A, respectively. The imputation method used for pruritus and hyperpigmentation was last observation carried forward. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2013 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Jeff Donovan, MD, PhD, FRCPC  JAAD Case Reports 

Jeff Donovan, MD, PhD, FRCPC  JAAD Case Reports 
Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients  Lily Chen, BA, Feng Gao, MD, PhD, MPH,
Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.
Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,

Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients  Patrizia Weber, MD, S. Morteza Seyed Jafari,
A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: A randomized, physician-blinded,

A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: A randomized, physician-blinded,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Psoriasis is associated with lipid abnormalities at the onset of skin disease  Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD 

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD 
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
Combined acitretin and Candida antigen versus either agent alone in the treatment of recalcitrant warts  Ahmad Nofal, MD, Fathia Khattab, MD, Eman Nofal,

Combined acitretin and Candida antigen versus either agent alone in the treatment of recalcitrant warts  Ahmad Nofal, MD, Fathia Khattab, MD, Eman Nofal,
María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

Similar presentations

Ads by Google